Unintended Interruption of Caplacizumab Therapy Can Compromise Outcomes in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Lessons from Two Clinical Cases.

Özcan F, Kiziler F, Brinkkoetter P, Kühne L, Knöbl P, Brinkhoff A

Open source

DOI
10.3390/jcm15176601
Published
2026 Aug 26
Container
Journal of clinical medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/jcm15176601,
  title = {Unintended Interruption of Caplacizumab Therapy Can Compromise Outcomes in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Lessons from Two Clinical Cases.},
  author = {Özcan F and Kiziler F and Brinkkoetter P and Kühne L and Knöbl P and Brinkhoff A},
  year = {2026},
  journal = {Journal of clinical medicine},
  doi = {10.3390/jcm15176601},
  url = {https://doi.org/10.3390/jcm15176601}
}

RIS

TY  - JOUR
TI  - Unintended Interruption of Caplacizumab Therapy Can Compromise Outcomes in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Lessons from Two Clinical Cases.
AU  - Özcan F
AU  - Kiziler F
AU  - Brinkkoetter P
AU  - Kühne L
AU  - Knöbl P
AU  - Brinkhoff A
PY  - 2026
JO  - Journal of clinical medicine
DO  - 10.3390/jcm15176601
UR  - https://doi.org/10.3390/jcm15176601
ER  - 

APA

F, Ö., F, K., P, B., L, K., P, K., & A, B. (2026). Unintended Interruption of Caplacizumab Therapy Can Compromise Outcomes in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Lessons from Two Clinical Cases.. Journal of clinical medicine. https://doi.org/10.3390/jcm15176601

Source records